• Price (USD)32.57
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change-11.13%
  • Beta--
Data delayed at least 20 minutes, as of Nov 28 2022 15:27 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.

  • Revenue in USD (TTM)4.40bn
  • Net income in USD-86.20m
  • Incorporated2013
  • Employees9.90k
  • Location
    Perrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
  • Phone+353 17094000
  • Websitehttps://www.perrigo.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRGO:NYQ since
Nestle SA-Gateway Infant Formula Plant,Eau Claire, WisconsinDeal completed01 Nov 202201 Nov 2022Deal completed-20.33%170.00m
Data delayed at least 15 minutes, as of Nov 29 2022 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.